In Metastatic Uveal Melanoma, New Drug Improves Progression-Free Survival, Shrinks Tumors

on

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented at the 49th annual meeting of the American Society of Clinical Oncology (ASCO). The findings are potentially practice-changing for a historically “untreatable disease…